Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept Continuous vs Intermittent Therapy in Psoriasis (CRYSTEL)
NCT00195507Phase 4Completed
- Sponsor
- Pfizer
- Start
- Dec 2004
- Modality
- Fc-Fusion Proteins
- Countries
- 19
01
Overview
Phase 4, randomised, open-label trial of etanercept in plaque psoriasis (2 arms), sponsored by Pfizer. Primary endpoint: Physician Global Assessment of Psoriasis at 54 weeks. Started Dec 2004; status: completed.
02
Drugs
etanercept
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00195507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00195507.